Introduction
Acute viral hepatitis is a significant cause of jaundice during pregnancy, resulting from both pregnancy-specific conditions, such as acute fatty liver of pregnancy and HELLP syndrome (hemolysis, elevated liver enzymes, and low platelet count), and general viral infections.[1][2] Hepatitis caused by viruses A, B, C, D, and E presents unique challenges regarding transmission, gestational complications, immunization, and breastfeeding. Diagnosis of viral hepatitis in pregnancy relies on serologic markers, and management strategies focus on reducing maternal and fetal complications while supporting safe breastfeeding practices.
Etiology
Register For Free And Read The Full Article
Search engine and full access to all medical articles
10 free questions in your specialty
Free CME/CE Activities
Free daily question in your email
Save favorite articles to your dashboard
Emails offering discounts
Learn more about a Subscription to StatPearls Point-of-Care
Etiology
Hepatitis A
Hepatitis A virus (HAV) is a positive-sense, single-stranded RNA virus belonging to the family Picornaviridae with a single serotype worldwide.[3] The virus is mainly transmitted through the fecal-oral route and is most prevalent in developing countries with poor hygiene and sanitation due to food and water contamination. The virus can be transmitted through sexual contact and rarely through blood exposure in injecting drug users during a blood transfusion. The average incubation period for HAV is 30 days. HAV has the highest concentration in the feces, serum, and saliva, respectively. HAV is also transmitted through sexual contact. Chronic sequelae among persons infected with HAV have not been reported. Intrauterine and perinatal transmission of HAV is a rare occurrence.[4][5]
Hepatitis B
Hepatitis B virus (HBV) is an enveloped, partially double-stranded virus with a circular DNA genome belonging to the family Hepadnavirus. Chronic HBV infection is associated with cirrhosis and hepatocellular carcinoma. HBV does not cross the placenta and cannot infect the fetus unless there have been breaks in the maternal-fetal barrier. Perinatal transmission accounts for more than 50% of cases worldwide. Pregnant women with chronic HBV and positive HBV E antigen (HBeAg) have a 90% likelihood of their newborns being infected with HBV.[6] Other modes of transmission include sexual intercourse, body fluids, and blood transfusion.
Hepatitis C
Hepatitis C virus (HCV) is a partially double-stranded, plus-sense RNA virus with 11 major genotypes and 15 subtypes.[7] Acute HCV infection occurs during the first 6 months after exposure. Failure to clear the HCV after 6 months would progress to chronic HCV. HCV is a significant cause of cirrhosis and hepatocellular carcinoma worldwide. The primary mode of transmission of HCV is mostly through parental transmission, which includes infected blood transmission, intravenous drug users sharing needles, sexual contact, and mother-to-child transmission.[8] Vertical (mother-to-child) transmission is the leading cause of HCV infection in children. Perinatal transmission of HCV is mainly during the last month of pregnancy or delivery. Invasive procedures, eg, amniocentesis and chronic villus sampling, break the maternal-fetal barrier. This increases the risk of vertical transmission of HCV during pregnancy and delivery.
Hepatitis D
Hepatitis D (HDV) is caused by the hepatitis delta virus, a single-stranded, circular RNA, and a defective virus with an incomplete RNA requiring the assistance of the HBV, specifically HBV surface antigen (HBsAg), to be infectious.[9] HDV is transmitted chiefly through the same route as HBV. The parenteral mode is the primary transmission mode, and vertical transmission during pregnancy is rare. Coinfection of HDV and HBV leads to severe acute infection. Superinfection of the HDV on chronic HBV leads to higher progression to chronic HDV.
Hepatitis E
Hepatitis E virus (HEV) is an icosahedral, nonenveloped virus with a single-stranded, positive RNA virus classified into the family Hepeviridae and the genus Orthohepeviurs. About 7 genotypes of the HEV have been identified, and genotypes 1 to 4 are known to affect humans.[10] The main transmission route for HEV infection is the fecal-oral route and is most prevalent in developing countries with poor sanitation. Vertical transmission of the HEV varies between 23.3% and 50%. Sporadic cases not associated with travel have been reported in developed countries, and this is mainly caused by genotype 3, which is primarily attributed to the immunocompromised state.[11] HEV has rarely been reported to be transmitted through sexual intercourse.
Epidemiology
Hepatitis A
HAV is most prevalent in developing countries. 1:1000 pregnant women are infected with acute HAV. The disease is mainly self-limited, with a mortality of 0.3% to 0.6%.[12]
Hepatitis B
HBV affects more than 250 million individuals worldwide and is the most common cause of chronic hepatitis worldwide. Approximately 65 million women of childbearing age are infected with chronic HBV. About 800,000 to 1.4 million people are infected with HBV in the United States. A 0.7% to 0.9% prevalence of chronic HBV infection among pregnant women in the United States has been noted.[13]
Hepatitis C
HCV affects more than 170 million people worldwide. About 8% of pregnant women are infected with HCV. The estimated prevalence of antenatal HCV infection in the United States is 1% to 2.5%.[14]
Hepatitis D
HDV affects 15 to 20 million people worldwide with HBV carriers. New studies estimate the prevalence of HDV to be closer to 62 to 72 million. The prevalence of HDV in the United States is estimated to range from 2% to 50%, depending on the patient population.[15] The prevalence of HDV in a study in Pakistan revealed an estimated 20.63% of pregnant women with chronic HBV infection.
Hepatitis E
HEV affects about 20.1 million new infections. HEV infection is prevalent in developing countries. HEV infection accounts for 70,000 deaths and 3000 stillbirths yearly.[16] Pregnant women in the second and third trimesters are mostly affected during epidemics. The mortality rate is as high as 5% to 25%, and a higher mortality rate is associated with pregnant women who progressed to fulminant hepatitis.
History and Physical
Acute viral hepatitis in pregnancy could be asymptomatic or have mild clinical disease. Patients may present with nonspecific symptoms, eg, jaundice, nausea, anorexia, abdominal pain or discomfort, fatigue, malaise, myalgia, and dark urine. Clinical symptoms are unable to differentiate the various viral hepatitides. Pregnant women with chronic HBV and HCV infection may progress to decompensated cirrhosis and develop ascites, hepatic encephalopathy, coagulopathy, thrombocytopenia, spontaneous bacterial peritonitis, and esophageal variceal bleeding.[17] The most common presentation of viral hepatitis is jaundice. Other nonspecific symptoms include fever, myalgia, abdominal pain, nausea, vomiting, and to mention a few.
Evaluation
The liver function test is assessed as the initial biomarker elevated in acute viral hepatitis. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) are elevated during the acute episode. ALT is elevated 2-to-100 fold depending on the severity of the acute viral hepatitis. International normalized ratio (INR), prothrombin time (PT), albumin, and ammonia are evaluated for acute and chronic viral hepatitis infections.
Hepatitis A
Pregnant women who had contact with persons with acute HAV should be screened for acute HAV infection. HAV viral infection is diagnosed by detecting the immunoglobulin M antibody to the hepatitis A (anti-HAV IgM) virus in pregnant women and the fetus/newborn.
Hepatitis B
Vertical transmission of HBV from infected mothers to their fetuses or newborns results in a 90% likelihood of the newborn getting infected if the pregnant woman has chronic HBV and is positive for HBeAg.[6] The United States Preventive Services recommended universal screening for HBV infection during pregnancy at the first prenatal visit, as well as the Task Force (USPSTF) and the American Congress of Obstetricians and Gynecologists (ACOG). Thus, every pregnant woman should be screened for the HBV surface antigen at the initial visit. This is to decrease the mother-to-child transmission of HBV. HBV DNA should be measured during the second trimester at weeks 26 to 28.[18]
Hepatitis C
Transmission is associated with higher levels of HCV RNA in pregnant women. The American College of Obstetricians and Gynecologists (ACOG) and the Centers for Disease Control and Prevention (CDC) recommend risk-based screening for HCV in pregnant women. The anti-HCV antibody is tested as a screening tool during pregnancy.
Hepatitis D
World Health Organization (WHO) recommends screening pregnant women infected with HBV for HDV. Serum immunoglobulin M anti-HDAg is detected during active infection.
Hepatitis E
Pregnant women in the second and third trimesters are mostly affected during epidemics. The mortality rate is as high as 5% to 25%. There is a higher mortality rate in pregnant women who progressed to fulminant hepatitis. Anti-HEV IgM is tested during pregnancy for suspected cases.
Treatment / Management
Hepatitis A
Administer hepatitis A immunoglobulin to pregnant women who had contact with persons with acute HAV infection and newborns infected during the third trimester. Newborns are to receive hepatitis A immunoglobulin within 48 hours of birth, as recommended by the Centers for Disease Control (CDC) and the American College of Pediatric Association.[19] A minimal risk of transmission of HAV via breastmilk is present. The benefit of breastfeeding greatly outweighs stopping breastfeeding. No contraindication to breastfeeding for mothers infected with HAV has been established.
Hepatitis B
Pregnant women with immune active HBeAg-positive immune-active phase, cirrhosis, and advanced fibrosis should be treated in pregnancy.[18] Hepatitis B immunoglobulin and hepatitis B vaccine should be administered within 12 to 24 hours of birth to all babies of HBsAg mothers or those with unknown/undocumented HBsAg status, followed by 2 other doses of vaccination at 1 month and 6 months. This is regardless of whether maternal antiviral therapy was administered during the pregnancy. Low birth weight neonates weighing less than 2 kg and preterm neonates should receive Hepatitis B immunoglobulin at birth 1 month, 3 months, and 7 months.[20]
Implementing this approach has reduced the risk of exposure from 90% to 5% to 10% in exposed neonates. Decreasing vertical HBV transmission through cesarean section is not recommended as the sole indication.[21] Using antiviral therapy, eg, tenofovir, telbivudine, or lamivudine after 28 to 32 weeks of gestation in HBV-infected pregnant women with high viral load (>200,000 IU/mL or >6-8 log 10 copies/mL) has been associated with <3% risk of transmission. The new WHO guidelines recommend treatment for HBV-infected pregnant women with high viral load >200,000 IU/mL and HBeAg-positive.[22](A1)
Tenofovir is the preferred antiviral therapy with a lower risk of resistance and is associated with low mineral bone loss in neonates.[23] The administration of both hepatitis B immunoglobulin and hepatitis B vaccine HBV vaccine within 12 to 24 hours of birth to reduce in-utero infection has been recommended by the European Association for the Study of Liver Disease and the SMFM.[24] Fetal exposure risk has not been increased with the use of these antiviral medications during pregnancy.[25] Breastfeeding is encouraged after newborns receive the appropriate immunoprophylaxis by the American College of Pediatrics, Centers for Disease Control and Prevention (CDC), ACOG, and SMFM.(B2)
Hepatitis C
ACOG and the SMFM recommend against doing a cesarean section solely to reduce HCV transmission during pregnancy. Chronic HCV is treated with direct antiviral agents before pregnancy. The safety profile in pregnancy for women taking direct antiviral agents has not yet been established. Direct antiviral agent treatment is mostly deferred until postpartum.[26] Currently, there is no immunization for HCV-infected mothers and infants. No contraindication to breastfeeding has been identified in HCV-infected mothers and infants.
Hepatitis D
HDV infection is treated with long-term alpha interferon and PEGylated interferon, both of which are contraindicated during pregnancy. Due to perinatal prevention and treatment of HBV infection, transmission of HDV has largely decreased.
Hepatitis E
Hepatitis E viral infection is associated with a severe disease course. HEV recombinant protein vaccine was noted to be effective in decreasing HEV transmission in developing countries. This is currently unavailable in developed countries. Safety and efficacy in pregnant women have not been studied. No contraindication to breastfeeding has been identified in mothers infected with the HEV.
Differential Diagnosis
The differential diagnosis of pregnancy and viral hepatitis includes:
- Acute fatty liver of pregnancy
- Hyperemesis gravidarum
- Intrahepatic cholestasis of pregnancy
- Severe preeclampsia
- HELLP syndrome (hemolysis, elevated liver enzymes, and low platelet count)
- Herpes simplex virus hepatitis
- Epstein-Barr viral hepatitis.
Prognosis
Chronic sequelae among persons infected with HAV have not been reported. The 2nd and 3rd trimesters are associated with higher mortality of 5% to 25% in HEV infection. Pregnant women are likely to progress to fulminant hepatitis.
Complications
Hepatitis A
HAV has been associated with gestational complications, including premature contractions, placental separation, premature rupture of membranes, and vaginal bleeding. These have been reported in a study evaluating the impact of acute HAV in pregnancy.[27] Fetal ascites and meconium peritonitis, which is a rare occurrence, have been reported.[4]
Hepatitis B
The adverse effect of HBV on pregnancy is rare in patients with acute or chronic HBV infection. Increased maternal and perinatal death is associated with the HBV infection during pregnancy. The most common cause of maternal mortality of HBV-related cirrhosis was variceal hemorrhage.[28] Placenta abruption, preterm birth, gestational hypertension, and fetal growth restriction have been associated with chronic HBV during pregnancy. Chronic HBV in pregnancy increases the risk of progression to cirrhosis.
Hepatitis C
Fetal growth restriction, brachial plexus injury, fetal distress, cephalohematoma, neonatal seizures, and intraventricular hemorrhage are gestational complications observed in HCV-infected pregnant women.[29]
Hepatitis D
Chronic HDV is associated with a high risk of severe chronic liver disease in pregnant women.
Hepatitis E
Obstetric complications reported in studies include premature rupture of membranes, antepartum and postpartum hemorrhage, disseminated intravascular coagulation (DIC), intrauterine fetal deaths, spontaneous abortions, stillbirths, and complications of fulminant hepatitis.[30] Fetal complications from the HEV include preterm and low birth weights.
Deterrence and Patient Education
The US Preventative Services has recommended universal screening for mothers to screen for HBV during pregnancy at the first prenatal visit using HBsAg and Task Force (USPSTF) and ACOG. Breastfeeding is encouraged after newborns with exposure to HBV receive the appropriate immunoprophylaxis by the American College of Pediatrics, Centers for Disease Control and Prevention (CDC), ACOG, and SMFM. No immunization for HCV-infected mothers and infants has been established, and no contraindication for breastfeeding in HCV-infected mothers and infants. Pregnant women in developed countries should avoid traveling to the HEV endemic regions.
Enhancing Healthcare Team Outcomes
Effective management of viral hepatitis in pregnancy requires a collaborative approach among physicians, advanced practitioners, nurses, pharmacists, and other healthcare professionals to deliver patient-centered care and improve outcomes. Physicians and advanced practitioners play a vital role in early identification by adhering to screening guidelines for HBV and HCV during pregnancy and implementing evidence-based management strategies. Nurses contribute significantly by providing patient education, fostering adherence to follow-up care, and coordinating interventions to support maternal and neonatal health. Pharmacists ensure the safe and effective use of antiviral therapies, particularly in managing maternal viral loads, to reduce the risk of vertical transmission.
Strong interprofessional communication is essential to ensure seamless care transitions, such as coordinating timely immunoprophylaxis and follow-up testing for newborns exposed to HBV or HCV. Care coordination and shared decision-making among healthcare professionals help address patient concerns, align treatment plans with individual preferences, and build trust. These collaborative efforts enhance patient safety, optimize maternal and neonatal outcomes, and improve overall team performance, fostering a comprehensive approach to managing viral hepatitis in pregnancy.
References
Mishra L, Seeff LB. Viral hepatitis, A though E, complicating pregnancy. Gastroenterology clinics of North America. 1992 Dec:21(4):873-87 [PubMed PMID: 1478741]
Brady CW. Liver Disease in Pregnancy: What's New. Hepatology communications. 2020 Feb:4(2):145-156. doi: 10.1002/hep4.1470. Epub 2020 Jan 6 [PubMed PMID: 32025601]
Lemon SM, Ott JJ, Van Damme P, Shouval D. Type A viral hepatitis: A summary and update on the molecular virology, epidemiology, pathogenesis and prevention. Journal of hepatology. 2017 Sep 5:():. pii: S0168-8278(17)32278-X. doi: 10.1016/j.jhep.2017.08.034. Epub 2017 Sep 5 [PubMed PMID: 28887164]
Leikin E, Lysikiewicz A, Garry D, Tejani N. Intrauterine transmission of hepatitis A virus. Obstetrics and gynecology. 1996 Oct:88(4 Pt 2):690-1 [PubMed PMID: 8841254]
Level 3 (low-level) evidenceRadivojevic K, Rosenkranz M, Weninger M. [Intrauterine transmission of hepatitis A: a case report]. Gynakologische Rundschau. 1989:29(3):186-8 [PubMed PMID: 2807030]
Level 3 (low-level) evidenceJoshi SS, Coffin CS. Hepatitis B and Pregnancy: Virologic and Immunologic Characteristics. Hepatology communications. 2020 Feb:4(2):157-171. doi: 10.1002/hep4.1460. Epub 2020 Jan 2 [PubMed PMID: 32025602]
Simmonds P. Viral heterogeneity of the hepatitis C virus. Journal of hepatology. 1999:31 Suppl 1():54-60 [PubMed PMID: 10622561]
Mok J, Pembrey L, Tovo PA, Newell ML, European Paediatric Hepatitis C Virus Network. When does mother to child transmission of hepatitis C virus occur? Archives of disease in childhood. Fetal and neonatal edition. 2005 Mar:90(2):F156-60 [PubMed PMID: 15724041]
Taylor JM. Structure and replication of hepatitis delta virus RNA. Current topics in microbiology and immunology. 2006:307():1-23 [PubMed PMID: 16903218]
Pérez-Gracia MT, Suay-García B, Mateos-Lindemann ML. Hepatitis E and pregnancy: current state. Reviews in medical virology. 2017 May:27(3):e1929. doi: 10.1002/rmv.1929. Epub 2017 Mar 20 [PubMed PMID: 28318080]
Charre C, Ramière C, Dumortier J, Abravanel F, Lhomme S, Gincul R, Scholtès C. Chronic Genotype 3 Hepatitis E in Pregnant Woman Receiving Infliximab and Azathioprine. Emerging infectious diseases. 2018 May:24(5):941-943. doi: 10.3201/eid2405.171845. Epub [PubMed PMID: 29664396]
Chaudhry SA, Koren G. Hepatitis A infection during pregnancy. Canadian family physician Medecin de famille canadien. 2015 Nov:61(11):963-4 [PubMed PMID: 26881283]
Smith EA, Jacques-Carroll L, Walker TY, Sirotkin B, Murphy TV. The national Perinatal Hepatitis B Prevention Program, 1994-2008. Pediatrics. 2012 Apr:129(4):609-16. doi: 10.1542/peds.2011-2866. Epub 2012 Mar 26 [PubMed PMID: 22451702]
Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. The Lancet. Infectious diseases. 2005 Sep:5(9):558-67 [PubMed PMID: 16122679]
Chen HY, Shen DT, Ji DZ, Han PC, Zhang WM, Ma JF, Chen WS, Goyal H, Pan S, Xu HG. Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis. Gut. 2019 Mar:68(3):512-521. doi: 10.1136/gutjnl-2018-316601. Epub 2018 Sep 18 [PubMed PMID: 30228220]
Level 1 (high-level) evidenceChaudhry SA, Verma N, Koren G. Hepatitis E infection during pregnancy. Canadian family physician Medecin de famille canadien. 2015 Jul:61(7):607-8 [PubMed PMID: 26175368]
Ginès P, Krag A, Abraldes JG, Solà E, Fabrellas N, Kamath PS. Liver cirrhosis. Lancet (London, England). 2021 Oct 9:398(10308):1359-1376. doi: 10.1016/S0140-6736(21)01374-X. Epub 2021 Sep 17 [PubMed PMID: 34543610]
Bzowej NH. Optimal Management of the Hepatitis B Patient Who Desires Pregnancy or Is Pregnant. Current hepatitis reports. 2012 Jun:11(2):82-89 [PubMed PMID: 22707918]
Advisory Committee on Immunization Practices (ACIP), Fiore AE, Wasley A, Bell BP. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports. 2006 May 19:55(RR-7):1-23 [PubMed PMID: 16708058]
Hou J, Cui F, Ding Y, Dou X, Duan Z, Han G, Jia J, Mao Q, Li J, Li Z, Liu Z, Wei L, Xie Q, Yang X, Zhang H, Zhuang H. Management Algorithm for Interrupting Mother-to-Child Transmission of Hepatitis B Virus. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2019 Sep:17(10):1929-1936.e1. doi: 10.1016/j.cgh.2018.10.007. Epub 2018 Oct 9 [PubMed PMID: 30312789]
Chang MS, Gavini S, Andrade PC, McNabb-Baltar J. Caesarean section to prevent transmission of hepatitis B: a meta-analysis. Canadian journal of gastroenterology & hepatology. 2014 Sep:28(8):439-44 [PubMed PMID: 25229465]
Level 1 (high-level) evidenceWorld Health Organization. Guidelines for the Prevention, Diagnosis, Care and Treatment for People with Chronic Hepatitis B Infection (Text Extract): Executive Summary. Infectious diseases & immunity. 2024 Jul:4(3):103-105. doi: 10.1097/ID9.0000000000000128. Epub 2024 Jun 12 [PubMed PMID: 39391287]
Siberry GK, Jacobson DL, Kalkwarf HJ, Wu JW, DiMeglio LA, Yogev R, Knapp KM, Wheeler JJ, Butler L, Hazra R, Miller TL, Seage GR 3rd, Van Dyke RB, Barr E, Davtyan M, Mofenson LM, Rich KC, Pediatric HIV/AIDS Cohort Study. Lower Newborn Bone Mineral Content Associated With Maternal Use of Tenofovir Disoproxil Fumarate During Pregnancy. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2015 Sep 15:61(6):996-1003. doi: 10.1093/cid/civ437. Epub 2015 Jun 9 [PubMed PMID: 26060285]
Pan CQ, Han GR, Jiang HX, Zhao W, Cao MK, Wang CM, Yue X, Wang GJ. Telbivudine prevents vertical transmission from HBeAg-positive women with chronic hepatitis B. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2012 May:10(5):520-6. doi: 10.1016/j.cgh.2012.01.019. Epub 2012 Feb 14 [PubMed PMID: 22343511]
Level 2 (mid-level) evidenceEhrhardt S, Xie C, Guo N, Nelson K, Thio CL. Breastfeeding while taking lamivudine or tenofovir disoproxil fumarate: a review of the evidence. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2015 Jan 15:60(2):275-8. doi: 10.1093/cid/ciu798. Epub 2014 Oct 13 [PubMed PMID: 25313254]
Society for Maternal-Fetal Medicine (SMFM). Electronic address: pubs@smfm.org, Hughes BL, Page CM, Kuller JA. Hepatitis C in pregnancy: screening, treatment, and management. American journal of obstetrics and gynecology. 2017 Nov:217(5):B2-B12. doi: 10.1016/j.ajog.2017.07.039. Epub 2017 Aug 4 [PubMed PMID: 28782502]
Elinav E, Ben-Dov IZ, Shapira Y, Daudi N, Adler R, Shouval D, Ackerman Z. Acute hepatitis A infection in pregnancy is associated with high rates of gestational complications and preterm labor. Gastroenterology. 2006 Apr:130(4):1129-34 [PubMed PMID: 16618407]
Rasheed SM, Abdel Monem AM, Abd Ellah AH, Abdel Fattah MS. Prognosis and determinants of pregnancy outcome among patients with post-hepatitis liver cirrhosis. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. 2013 Jun:121(3):247-51. doi: 10.1016/j.ijgo.2012.12.020. Epub 2013 Mar 19 [PubMed PMID: 23518137]
Salemi JL, Whiteman VE, August EM, Chandler K, Mbah AK, Salihu HM. Maternal hepatitis B and hepatitis C infection and neonatal neurological outcomes. Journal of viral hepatitis. 2014 Nov:21(11):e144-53. doi: 10.1111/jvh.12250. Epub 2014 Mar 26 [PubMed PMID: 24666386]
Level 2 (mid-level) evidencePatra S, Kumar A, Trivedi SS, Puri M, Sarin SK. Maternal and fetal outcomes in pregnant women with acute hepatitis E virus infection. Annals of internal medicine. 2007 Jul 3:147(1):28-33 [PubMed PMID: 17606958]